Nina Wagner-Johnston

Associate Professor

19992020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Letter
2019

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

Hamlin, P. A., Flinn, I. W., Wagner-Johnston, N., Burger, J. A., Coffey, G. P., Conley, P. B., Michelson, G., Leeds, J. M., Der, K., Kim, Y., Sabalvaro-Torres, A., Birrell, M., Pandey, A., Curnutte, J. T. & Patel, M. R., Apr 2019, In : American journal of hematology. 94, 4, p. E90-E93

Research output: Contribution to journalLetter

2017

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Salles, G., Schuster, S. J., De Vos, S., Wagner-Johnston, N. D., Viardot, A., Blum, K. A., Flowers, C. R., Jurczak, W. J., Flinn, I. W., Kahl, B. S., Martin, P., Kim, Y., Shreay, S., Will, M., Sorensen, B., Breuleux, M., Zinzani, P. L. & Gopal, A. K., Mar 31 2017, In : Haematologica. 102, 4, p. e156-e159

Research output: Contribution to journalLetter

2016

Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria

Rashidi, A., Oak, E., Carson, K. R., Wagner-Johnston, N. D., Kreisel, F. & Bartlett, N. L., May 3 2016, In : Leukemia and Lymphoma. 57, 5, p. 1191-1193 3 p.

Research output: Contribution to journalLetter

2012

Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

Wagner-Johnston, N. D., Bartlett, N. L., Cashen, A. & Berger, J. R., Nov 1 2012, In : Leukemia and Lymphoma. 53, 11, p. 2283-2286 4 p.

Research output: Contribution to journalLetter